Lupin and Nichi-lko enter into strategic partnership

For commercialization of biosimilar Etanercept in Japan

Lupin and Nichi-lko announced that the two companies have entered into an agreement for the distribution, promotion and sale of Lupin's recently-filed biosimilar Etanercept (YL5113) in Japan.

Developed by YL Biologics, a joint venture between Lupin's subsidiary Lupin Atlantis Holdings SA(LAHSA) and Yoshindo, the product will be launched by Nichi-lko after receiving approval from the Pharmaceuticals and Medical Devices Agency (PMDA).

Powered by Capital Market - Live News